Mavenir Acquires Telestax to Enhance Its Business Messaging and Customer Engagement Platform with CPaaS
25.8.2021 14:15:00 EEST | Business Wire | Press release
Mavenir, the global leader in mobile messaging and business messaging monetization solutions for service providers, announced today that it has acquired Telestax Inc., a leading global Communications Platform as a Service (CPaaS) enablement and application provider to the communications industry. This acquisition enhances Mavenir Engage, Mavenir’s omni-channel messaging monetization and customer engagement offerings by:
- enabling service providers with new agile, nimble SaaS service models to better compete in the new digital economy
- delivering specialization, flexibility, and simplicity to meet the needs of businesses of all sizes across a broad spectrum of industry verticals
- providing service innovation and feature velocity with easy-to-consume APIs and business-critical applications
“Communication Platforms are becoming a key differentiator for service providers,” said Pardeep Kohli, President and CEO, Mavenir. “They will unlock enterprise value in 5G with API enablement for different verticals such as IoT, Smart Cities, Automotive and provide turnkey applications for logistics, fleet management, AI/ML chatbots, voice biometrics verification, immersive commerce/entertainment and many other use cases.”
“The early definition of CPaaS in terms of PSTN connectivity has been augmented to include a much broader range of services. Vendors that provide the full communication service stack – including the API layer and network infrastructure – have a competitive advantage from those whose strategy primarily focuses on the API layer and relies on partnerships to provide access to the network layer,”1 said Raúl Castañón-Martínez, Sr. Analyst, Workforce Productivity and Collaboration at 451 Research, a division of S&P Global Market Intelligence. According to 451 Research's Workforce Productivity & Collaboration 2021 CPaaS Market Monitor, total market revenue increased by well over 40% to $6.5bn in 2020, and will account for roughly $21bn in 2025, a CAGR of 26%.
“CPaaS is the key enabling technology for our Mavenir Engage service to position Communications Service Providers (CSPs) at the forefront of the digital engagement landscape,” said Ian Maclean, SVP/GM Cloud Services at Mavenir, “With this acquisition, Mavenir is lowering the barrier of entry and democratizing business messaging for businesses of all sizes to implement conversational commerce experiences.”
Mavenir Engage is Mavenir’s cloud-based messaging monetization and customer engagement offering that provides CSPs, systems integrators and channel partners with RCS Business Messaging (RBM), messaging monetization capabilities, chatbots, campaign management, and access to different messaging ecosystems—such as Google RCS Business Messaging.
Clark Peterson, Chairman, Cloud Communications Alliance, said: “Telestax has been a key partner to help drive the transformation of the CPaaS industry. Being part of the Mavenir family brings the breadth of portfolio to add new capabilities and further advance innovative customer offerings in Cloud Communications.”
Mavenir empowers service providers to give enterprises the ability to optimize workflows and customize business applications to better engage customers and employees. Eliminating complexity for their employees, increasing productivity and, most importantly, delighting their customers with a better customer experience.
Jean Deruelle, co-founder and CTO, Telestax, said: “From our roots as an Open-Source communications disruptor that defined the CPaaS Enablement Market with the Restcomm API framework, we are incredibly excited to join forces and combine our capabilities with Mavenir’s extensive 5G and omni-channel messaging portfolio in the next step of our journey to keep helping carriers globally define the future of business communications.”
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
_____________________
1 451 Research, “Communications Platforms as a Service Market Guide 2021”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005157/en/
Contact information
Mavenir PR Contact:
Maryvonne Tubb
Mavenir
PR@mavenir.com
Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com
Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
